Caribou Biosciences

CRBU · NASDAQ

$0.519+$0.055 (+11.85%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.464

CRBU analyst rating

BuyConsensus of 8 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy4
Hold4
Underperform0
Sell0

12-month price target · 9 analysts

Average $12.09 (+2230.3% upside)

Low: $4.04
Now: $0.519
High: $33.60

Upgrades and downgrades

The latest rating actions, newest first

CRBU analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 8, 2026	Downgrade	Buy → Neutral	—	41%
Brookline Capital	Oct 7, 2026	Downgrade	Buy → Hold	—	40%
RBC Capital	Oct 7, 2026	Downgrade	Outperform → Sector Perform	$10.00 → $1.00	44%
Leerink Partners	Oct 7, 2026	Downgrade	Outperform → Market Perform	$4.00 → $1.00	38%
B of A Securities	Aug 14, 2026	Maintains	Buy	$6.00 → $5.00	36%
HC Wainwright & Co.	May 11, 2026	Maintains	Buy	$9.00 → $11.00	41%
HC Wainwright & Co.	Apr 7, 2026	Maintains	Buy	$9.00	41%
Evercore ISI Group	Mar 9, 2026	Maintains	Outperform	$11.00 → $13.00	9%
Clear Street	Feb 2, 2026	Initiates	Buy	$13.00	13%
HC Wainwright & Co.	Nov 5, 2025	Maintains	Buy	$3.00 → $9.00	41%

The case for and against

Updated Oct 16, 2026

Bull case

Caribou Biosciences is viewed positively because it is already in the clinic with allogeneic CAR-T programs targeting validated oncology antigens like CD19 and BCMA, giving it a clearer path to meaningful clinical readouts than many early-stage gene-editing peers. Its chRDNA platform appears differentiated by improving specificity and limiting off-target effects, while Pfizer’s $25 million equity investment adds external validation and supports the company’s technology and strategy. Financially, 1Q26 net loss was $0.26 per share, better than expected, with $118.6 million in cash, cash equivalents, and marketable securities supporting a runway into 2H27 and reducing near-term financing pressure.

Bear case

Caribou Biosciences is facing a weak fundamental profile because its value proposition rests on unproven clinical assets with only 60% and 35% assumed approval probabilities for vispa-cel and CB-011, while the DCF framework already embeds substantial uncertainty. The company has also announced it will discontinue further development of both allogeneic CAR-T programs and is pursuing strategic alternatives, signaling that financing constraints and lack of capital have undermined execution rather than supported growth. With $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, alongside non-revenue-generating status, potential dilution, and regulatory and competitive risks, the outlook remains materially pressured.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.